Magic Mushrooms For Anorexia? Clinical Study Receives FDA Approval For Phase 2 Trial
Origin Therapeutics Holdings Inc. (CSE: ORIG), a psychedelics industry-focused investment issuer, announced that one of its portfolio companies, Xpira Pharmaceuticals, has obtained approval from the FDA for its first Investigational New Drug (IND) application for a Phase 2a psilocybin therapy clinical study for anorexia nervosa.
